Loap Pierre, Scher Nathaniel, Goudjil Farid, Kirova Youlia, Girard Nicolas, Cao Kim I
Department of Radiation Oncology, Institut Curie, Paris, France.
Int J Part Ther. 2020 Nov 16;7(3):65-70. doi: 10.14338/IJPT-20-00023.1. eCollection 2021 Winter.
Thymic malignancies are the most common anterior mediastinal tumors. Advanced thymic carcinoma treatment relies on chemotherapy and definitive radiation therapy when possible. However, pericardial involvement is problematic for radiation therapy treatment planning owing to significant cardiac radiation exposure. We report the first case of definitive proton beam therapy (PBT) for an advanced thymic carcinoma with pericardial invasion.
We report the case of a 69-year-old patient treated with definitive radiation therapy for a stage IVB thymic carcinoma with pericardial invasion. Mean doses delivered to critical organs at risk were compared between deep inspiration breath-hold (DIBH) volumetric modulated arc therapy (VMAT) and DIBH-PBT.
When compared to DIBH-VMAT, DIBH-PBT reduced the mean doses delivered to the heart by 3.72 Gy (19.0% dose reduction), to the right lung by 5.9 Gy (41.7% dose reduction), to the left lung by 3.63 Gy (19.0% dose reduction), and to the esophagus by 3.57 Gy (21.3% dose reduction). Despite an early mediastinal relapse after 3.0 months, our patient is still alive after a 14-month follow-up, without any radiation-induced cardiac adverse events and is undergoing pembrolizumab-based immunotherapy.
Proton beam therapy is an option for definitive irradiation of thymic malignancies invading the pericardium; in this situation, PBT reduces doses to the heart and may help to reduce cardiotoxicity when compared with photon techniques.
胸腺恶性肿瘤是最常见的前纵隔肿瘤。晚期胸腺癌的治疗在可能的情况下依赖化疗和根治性放疗。然而,由于心脏受到显著的辐射暴露,心包受累对放射治疗计划来说是个难题。我们报告首例采用质子束治疗(PBT)晚期胸腺癌合并心包侵犯的病例。
我们报告一例69岁患者,接受了针对IVB期胸腺癌合并心包侵犯的根治性放疗。比较了深吸气屏气(DIBH)容积调强弧形放疗(VMAT)和DIBH-PBT对危及器官的平均剂量。
与DIBH-VMAT相比,DIBH-PBT使心脏的平均剂量降低了3.72 Gy(剂量降低19.0%),右肺降低了5.9 Gy(剂量降低41.7%),左肺降低了3.63 Gy(剂量降低19.0%),食管降低了3.57 Gy(剂量降低21.3%)。尽管3.0个月后出现早期纵隔复发,但我们的患者在14个月的随访后仍然存活,没有任何放疗引起的心脏不良事件,并且正在接受基于帕博利珠单抗(pembrolizumab)的免疫治疗。
质子束治疗是侵犯心包的胸腺恶性肿瘤根治性照射的一种选择;在这种情况下,与光子技术相比,PBT可降低心脏剂量,并可能有助于降低心脏毒性。